knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 01:12:38 - browse：954

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

focus

WSS

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

ReNAgade cuts staff seven months after raising $300 million

New report analyzes digital physical therapy solutions' effectiveness

'Essentially witchcraft:' A former naturopath takes on the field

Despite FDA concern, risk that CAR

Mayo Clinic plans $5B tech

hotspot

knowledge

explore

Moonlake's readout produced a cash windfall. Risks remain

Readers discuss the intersection of pregnancy and addiction

In age of alternative facts, a scholarly course on calling out crap

Pediatric cancer treatments threatened by a new FDA policy

23andMe had bad news about my health. I wish a person had delivered it

FDA investigates CAR

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Cigna, Humana reportedly in talks to merge

Sports medicine is finally prioritizing gender equality

J&J to emphasize cancer drugs, stop much of its vaccine research

knowledge

'Essentially witchcraft:' A former naturopath takes on the field

Organ aging and disease risk measured by new blood test

Cigna, Humana reportedly in talks to merge

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

30 years of 'Listening to Prozac'

What don’t we know about an Alzheimer’s drug side effect?

explore

focus

Wikipedia

hotspot